COX-2s pending approval may also carry heart risks

Share this article:
The FDA suggested two COX-2 drugs pending approval, Merck's Arcoxia and Novartis' Prexige, carry similar cardiovascular risks to Merck's Vioxx.
The FDA raised questions about the drugs in staff documents posted ahead of this week's joint-session on COX-2s to examine their risks and benefits.
The FDA said in the documents that there was an increase in the number of cardiovascular events and hypertension in people using Arcoxia.
The documents also said a study involving patients taking Prexige and patients taking naproxen showed there was an increase in the number of cardiac deaths and non-fatal heart attacks and strokes among those taking Prexige.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.